BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13(8): 1292-1294 [PMID: 17451219 DOI: 10.3748/wjg.v13.i8.1292]
URL: https://www.wjgnet.com/1007-9327/full/v13/i8/1292.htm
Number Citing Articles
1
Current awareness: Pharmacoepidemiology and drug safetyPharmacoepidemiology and Drug Safety 2007; 16(11): i doi: 10.1002/pds.1377
2
Xian-Ling Wang, Yi-Ming Mu, Zhao-Hui Lu, Ju-Ming Lu, Jing-Tao Dou, Chang-Yu Pan. Type 1 Diabetes Caused by Interferon α-2α in Polycythemia Vera TherapyDiabetes Care 2010; 33(11): e141 doi: 10.2337/dc10-1266
3
Current World LiteratureCurrent Opinion in Endocrinology, Diabetes & Obesity 2008; 15(2): 193 doi: 10.1097/MED.0b013e3282fba8b4
4
Current World LiteratureCurrent Opinion in Endocrinology, Diabetes & Obesity 2007; 14(5): 421 doi: 10.1097/MED.0b013e3282f0ca40
5
Paola Tarabini-Castellani, Leire Apraiz, Joseba Portu, José Manuel Agud. Diabetes mellitus en relación con tratamiento con interferónEnfermedades Infecciosas y Microbiología Clínica 2008; 26(2): 120 doi: 10.1157/13115550
6
Marna G. Bouwhuis, Stefan Suciu, Alessandro Testori, Wim H. Kruit, François Salès, Poulam Patel, Cornelis J. Punt, Mario Santinami, Alain Spatz, Timo L.M. ten Hagen, Alexander M.M. Eggermont. Phase III Trial Comparing Adjuvant Treatment With Pegylated Interferon Alfa-2b Versus Observation: Prognostic Significance of Autoantibodies—EORTC 18991Journal of Clinical Oncology 2010; 28(14): 2460 doi: 10.1200/JCO.2009.24.6264
7
Yuan-Yuan Lv, Bing-Yin Shi, Hui Guo. Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis BWorld Journal of Gastroenterology 2008; 14(29): 4713-4715 doi: 10.3748/wjg.14.4713
8
Corrado Betterle, Fabio Presotto. HCV Infection and Cryoglobulinemia2012; : 43 doi: 10.1007/978-88-470-1705-4_5
9
Hiroaki Yagyu, Kenta Okada, Shin Sato, Yumiko Yamashita, Nobukazu Okada, Jun-ichi Osuga, Shoichiro Nagasaka, Kentaro Sugano, Shun Ishibashi. Pegylated interferon-α2b and ribavirin combination therapy induces Hashitoxicosis followed by type 1 diabetes mellitusDiabetes Research and Clinical Practice 2012; 95(3): e52 doi: 10.1016/j.diabres.2011.11.016
10
Maria Xenou, Ioannis Zoupas, Dimitrios Lygnos, Evangelos Fousteris. Diabetic ketoacidosis as first presentation of latent autoimmune diabetes in adults in a patient with hashitoxicosis as first presentation of Hashimoto’s thyroiditis: a case reportJournal of Medical Case Reports 2022; 16(1) doi: 10.1186/s13256-022-03523-3
11
Yun Nah Lee, Soung Won Jeong, Jae Hee Lim, Yang Seon Ryu, Seong Ran Jeon, Sang Kyun Kim, Jae Young Jang, Young Seok Kim, Boo Sung Kim, Mi Oh Roh. Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis CThe Korean Journal of Hepatology 2010; 16(2): 187 doi: 10.3350/kjhep.2010.16.2.187
12
Reiko Oka, Naoki Hiroi, Rika Shigemitsu, Mariko Sue, Yasuo Oshima, Mayumi Yoshida-Hiroi. Type 1 Diabetes Mellitus Associated with Pegylated Interferon-α Plus Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature ReviewClinical Medicine Insights: Endocrinology and Diabetes 2011; 4: CMED.S7815 doi: 10.4137/CMED.S7815
13
Daniel Lewis, Corinna van den Heuvel, Michaela Kenneally, Roger W Byard. Methamphetamine use and the risk of diabetic ketoacidosisMedicine, Science and the Law 2022; 62(1): 39 doi: 10.1177/00258024211020936
14
Masayuki Hayashi, Yuko Kataoka, Kazushige Tachikawa, Hiroki Koguchi, Hiroshi Tanaka. Dual onset of type 1 diabetes mellitus and Graves’ disease during treatment with pegylated interferon α-2b and ribavirin for chronic hepatitis CDiabetes Research and Clinical Practice 2009; 86(2): e19 doi: 10.1016/j.diabres.2009.08.009
15
Linghuan Wang, Kang Chen, Meirong Wang, Zhaohui Lv, Weijun Gu, Xianling Wang, Qi Ni, Yiming Mu. Characteristics of Interferon-Associated Diabetes Mellitus in Past 30 Years: A ReviewHormone and Metabolic Research 2022; 54(03): 145 doi: 10.1055/a-1749-5716
16
Linghuan Wang, Binqi Li, He Zhao, Peixin Wu, Qingzhen Wu, Kang Chen, Yiming Mu. A systematic review and meta-analysis of endocrine-related adverse events associated with interferonFrontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.949003
17
Taiba Zornitzki, Stephen Malnick, Lyudmila Lysyy, Hilla Knobler. Interferon therapy in hepatitis C leading to chronic type 1 diabetesWorld Journal of Gastroenterology 2015; 21(1): 233-239 doi: 10.3748/wjg.v21.i1.233